EA024746B1 - Ингибитор регулирующей апоптотические сигналы киназы - Google Patents
Ингибитор регулирующей апоптотические сигналы киназы Download PDFInfo
- Publication number
- EA024746B1 EA024746B1 EA201491283A EA201491283A EA024746B1 EA 024746 B1 EA024746 B1 EA 024746B1 EA 201491283 A EA201491283 A EA 201491283A EA 201491283 A EA201491283 A EA 201491283A EA 024746 B1 EA024746 B1 EA 024746B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compound
- formula
- analysis
- dmso
- compounds
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title claims 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title claims 3
- 230000006907 apoptotic process Effects 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 184
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract description 24
- 102000020233 phosphotransferase Human genes 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 11
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 11
- 206010023421 Kidney fibrosis Diseases 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims description 43
- 210000004027 cell Anatomy 0.000 claims description 40
- 238000012360 testing method Methods 0.000 claims description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 31
- 241000700159 Rattus Species 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 230000005764 inhibitory process Effects 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- -1 benzyl esters Chemical class 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 21
- 208000020832 chronic kidney disease Diseases 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 20
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000004169 proteins and genes Human genes 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 206010012601 diabetes mellitus Diseases 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 241000282414 Homo sapiens Species 0.000 claims description 14
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 14
- 201000006370 kidney failure Diseases 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 14
- 210000003734 kidney Anatomy 0.000 claims description 13
- 239000002244 precipitate Substances 0.000 claims description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 230000037396 body weight Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000011541 reaction mixture Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 239000000543 intermediate Substances 0.000 claims description 8
- 229940126062 Compound A Drugs 0.000 claims description 7
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 239000003446 ligand Substances 0.000 claims description 7
- 230000035699 permeability Effects 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 238000009739 binding Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 6
- 201000002793 renal fibrosis Diseases 0.000 claims description 6
- 238000003786 synthesis reaction Methods 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000001640 apoptogenic effect Effects 0.000 claims description 5
- 230000027455 binding Effects 0.000 claims description 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- 102000007469 Actins Human genes 0.000 claims description 4
- 108010085238 Actins Proteins 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 210000000651 myofibroblast Anatomy 0.000 claims description 4
- 239000012044 organic layer Substances 0.000 claims description 4
- 230000026731 phosphorylation Effects 0.000 claims description 4
- 238000006366 phosphorylation reaction Methods 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000004608 Ureteral Obstruction Diseases 0.000 claims description 3
- 238000009825 accumulation Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000001054 cortical effect Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000005259 measurement Methods 0.000 claims description 3
- 230000008901 benefit Effects 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 210000000626 ureter Anatomy 0.000 claims description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 72
- 238000004458 analytical method Methods 0.000 claims 27
- 239000000758 substrate Substances 0.000 claims 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 16
- 239000000872 buffer Substances 0.000 claims 14
- 239000013641 positive control Substances 0.000 claims 11
- 230000002440 hepatic effect Effects 0.000 claims 10
- 210000001853 liver microsome Anatomy 0.000 claims 10
- 238000002474 experimental method Methods 0.000 claims 9
- 210000002381 plasma Anatomy 0.000 claims 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 8
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 8
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 8
- 238000011534 incubation Methods 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 238000003756 stirring Methods 0.000 claims 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 7
- 230000003228 microsomal effect Effects 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 238000003556 assay Methods 0.000 claims 6
- 239000002207 metabolite Substances 0.000 claims 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 5
- 229940098773 bovine serum albumin Drugs 0.000 claims 5
- 239000000047 product Substances 0.000 claims 5
- 238000007423 screening assay Methods 0.000 claims 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 4
- 108060001084 Luciferase Proteins 0.000 claims 4
- 239000005089 Luciferase Substances 0.000 claims 4
- 239000004472 Lysine Substances 0.000 claims 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims 4
- 102000001708 Protein Isoforms Human genes 0.000 claims 4
- 108010029485 Protein Isoforms Proteins 0.000 claims 4
- 229940124639 Selective inhibitor Drugs 0.000 claims 4
- 230000002255 enzymatic effect Effects 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims 4
- 239000002609 medium Substances 0.000 claims 4
- 239000002953 phosphate buffered saline Substances 0.000 claims 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 4
- 238000011084 recovery Methods 0.000 claims 4
- 239000006228 supernatant Substances 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 229960003604 testosterone Drugs 0.000 claims 4
- AXTUTVOXCLUJMK-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methylbenzoic acid;hydrochloride Chemical compound Cl.CC1=CC(F)=C(C(O)=O)C=C1N1C=C(C2CC2)N=C1 AXTUTVOXCLUJMK-UHFFFAOYSA-N 0.000 claims 3
- VWSFOEHQKFAAGN-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methylbenzonitrile Chemical compound CC1=CC(F)=C(C#N)C=C1N1C=C(C2CC2)N=C1 VWSFOEHQKFAAGN-UHFFFAOYSA-N 0.000 claims 3
- YSWOWAIEZYDOGB-UHFFFAOYSA-N 5-(5-cyclopropyl-2-sulfanylidene-1h-imidazol-3-yl)-2-fluoro-4-methylbenzonitrile Chemical compound CC1=CC(F)=C(C#N)C=C1N1C(S)=NC(C2CC2)=C1 YSWOWAIEZYDOGB-UHFFFAOYSA-N 0.000 claims 3
- KWHGHFBULZPCCX-UHFFFAOYSA-N 5-[(2-cyclopropyl-2-oxoethyl)amino]-2-fluoro-4-methylbenzonitrile Chemical compound CC1=CC(F)=C(C#N)C=C1NCC(=O)C1CC1 KWHGHFBULZPCCX-UHFFFAOYSA-N 0.000 claims 3
- GPWZGVIWTGDEMY-UHFFFAOYSA-N 5-amino-2-fluoro-4-methylbenzonitrile Chemical compound CC1=CC(F)=C(C#N)C=C1N GPWZGVIWTGDEMY-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 108010090804 Streptavidin Proteins 0.000 claims 3
- 230000001413 cellular effect Effects 0.000 claims 3
- 230000000052 comparative effect Effects 0.000 claims 3
- 238000000502 dialysis Methods 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 210000003494 hepatocyte Anatomy 0.000 claims 3
- 239000010410 layer Substances 0.000 claims 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- 230000002503 metabolic effect Effects 0.000 claims 3
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims 3
- 229960003793 midazolam Drugs 0.000 claims 3
- 230000009871 nonspecific binding Effects 0.000 claims 3
- 239000008188 pellet Substances 0.000 claims 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims 3
- 238000012106 screening analysis Methods 0.000 claims 3
- 229940054269 sodium pyruvate Drugs 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims 2
- DNCLVDGUXUSPTL-UHFFFAOYSA-N 5-bromo-4-fluoro-2-methylaniline Chemical compound CC1=CC(F)=C(Br)C=C1N DNCLVDGUXUSPTL-UHFFFAOYSA-N 0.000 claims 2
- XSEGWEUVSZRCBC-UHFFFAOYSA-N 6beta-Hydroxytestosterone Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)O)C4C3CC(O)C2=C1 XSEGWEUVSZRCBC-UHFFFAOYSA-N 0.000 claims 2
- XSEGWEUVSZRCBC-ZVBLRVHNSA-N 6beta-hydroxytestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3C[C@@H](O)C2=C1 XSEGWEUVSZRCBC-ZVBLRVHNSA-N 0.000 claims 2
- VFMMPHCGEFXGIP-UHFFFAOYSA-N 7,8-Benzoflavone Chemical compound O1C2=C3C=CC=CC3=CC=C2C(=O)C=C1C1=CC=CC=C1 VFMMPHCGEFXGIP-UHFFFAOYSA-N 0.000 claims 2
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
- 108010009551 Alamethicin Proteins 0.000 claims 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 2
- 235000010469 Glycine max Nutrition 0.000 claims 2
- 244000068988 Glycine max Species 0.000 claims 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 2
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 claims 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 claims 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 239000004793 Polystyrene Substances 0.000 claims 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 2
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 claims 2
- 108010018242 Transcription Factor AP-1 Proteins 0.000 claims 2
- 102100023132 Transcription factor Jun Human genes 0.000 claims 2
- 229960000583 acetic acid Drugs 0.000 claims 2
- LGHSQOCGTJHDIL-UTXLBGCNSA-N alamethicin Chemical compound N([C@@H](C)C(=O)NC(C)(C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)NC(C)(C)C(=O)N[C@H](C(=O)NC(C)(C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NC(C)(C)C(=O)NC(C)(C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](CO)CC=1C=CC=CC=1)C(C)C)C(=O)C(C)(C)NC(=O)[C@@H]1CCCN1C(=O)C(C)(C)NC(C)=O LGHSQOCGTJHDIL-UTXLBGCNSA-N 0.000 claims 2
- 239000000908 ammonium hydroxide Substances 0.000 claims 2
- 239000011324 bead Substances 0.000 claims 2
- 238000012742 biochemical analysis Methods 0.000 claims 2
- 229960002685 biotin Drugs 0.000 claims 2
- 235000020958 biotin Nutrition 0.000 claims 2
- 239000011616 biotin Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 2
- 229960001058 bupropion Drugs 0.000 claims 2
- 238000004364 calculation method Methods 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 230000002860 competitive effect Effects 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 229960001985 dextromethorphan Drugs 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 239000012091 fetal bovine serum Substances 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 229960002725 isoflurane Drugs 0.000 claims 2
- 229960004125 ketoconazole Drugs 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 239000012299 nitrogen atmosphere Substances 0.000 claims 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 2
- 239000010452 phosphate Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 229920000139 polyethylene terephthalate Polymers 0.000 claims 2
- 239000005020 polyethylene terephthalate Substances 0.000 claims 2
- 229920002223 polystyrene Polymers 0.000 claims 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims 2
- 239000008057 potassium phosphate buffer Substances 0.000 claims 2
- 229940076788 pyruvate Drugs 0.000 claims 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims 2
- 238000003753 real-time PCR Methods 0.000 claims 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 claims 2
- 238000004007 reversed phase HPLC Methods 0.000 claims 2
- 239000002356 single layer Substances 0.000 claims 2
- 239000012265 solid product Substances 0.000 claims 2
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 2
- 239000011550 stock solution Substances 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 229960005371 tolbutamide Drugs 0.000 claims 2
- 238000012546 transfer Methods 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims 1
- MNOQVNSRLYAHLG-AEULXZPHSA-N (2s,3r)-2-[(2z,5z)-octa-2,5,7-trienyl]-3-undecyloxirane Chemical compound CCCCCCCCCCC[C@H]1O[C@H]1C\C=C/C\C=C/C=C MNOQVNSRLYAHLG-AEULXZPHSA-N 0.000 claims 1
- ZMPAPJBFYQSNFM-UHFFFAOYSA-N 1-sulfanylimidazole Chemical compound SN1C=CN=C1 ZMPAPJBFYQSNFM-UHFFFAOYSA-N 0.000 claims 1
- 238000005160 1H NMR spectroscopy Methods 0.000 claims 1
- WCCCDMWRBVVYCQ-UHFFFAOYSA-N 2-bromo-1-cyclopropylethanone Chemical compound BrCC(=O)C1CC1 WCCCDMWRBVVYCQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- SJRHYONYKZIRPM-UHFFFAOYSA-N 4-hydroxytolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(CO)C=C1 SJRHYONYKZIRPM-UHFFFAOYSA-N 0.000 claims 1
- ANMJVFKRCBKCFN-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-2-fluoro-4-methylbenzoic acid Chemical compound CC1=CC(F)=C(C(O)=O)C=C1N1C=C(C2CC2)N=C1 ANMJVFKRCBKCFN-UHFFFAOYSA-N 0.000 claims 1
- ONHJPHNRRMKWHZ-UHFFFAOYSA-N 5-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-amine Chemical compound CC(C)N1C=NN=C1C1=CC=C(N)N=C1 ONHJPHNRRMKWHZ-UHFFFAOYSA-N 0.000 claims 1
- MPBBJHFKDHDIRZ-UHFFFAOYSA-N 6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-amine Chemical compound CC(C)N1C=NN=C1C1=CC=CC(N)=N1 MPBBJHFKDHDIRZ-UHFFFAOYSA-N 0.000 claims 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 claims 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 claims 1
- NDCWHEDPSFRTDA-VEHVCKHKSA-N 6a-hydrox-ypaclitaxel Chemical compound C12C3(OC(C)=O)COC3C(O)C(O)C2(C)C(=O)C(OC(=O)C)C(C2(C)C)=C(C)C(OC(=O)C(O)C(NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)CC2(O)C1OC(=O)[13C]1=[13CH][13CH]=[13CH][13CH]=[13CH]1 NDCWHEDPSFRTDA-VEHVCKHKSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
- 229940126639 Compound 33 Drugs 0.000 claims 1
- 208000006075 Cytochrome P-450 CYP2B6 Inhibitors Diseases 0.000 claims 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 239000012848 Dextrorphan Substances 0.000 claims 1
- 241000701867 Enterobacteria phage T7 Species 0.000 claims 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 claims 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- OQPLORUDZLXXPD-UHFFFAOYSA-N Hydroxymephenytoin Chemical compound C=1C=C(O)C=CC=1C1(CC)NC(=O)N(C)C1=O OQPLORUDZLXXPD-UHFFFAOYSA-N 0.000 claims 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 241000282553 Macaca Species 0.000 claims 1
- 241000282560 Macaca mulatta Species 0.000 claims 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 1
- 102000006386 Myelin Proteins Human genes 0.000 claims 1
- 108010083674 Myelin Proteins Proteins 0.000 claims 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 1
- 239000004677 Nylon Substances 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- 239000004809 Teflon Substances 0.000 claims 1
- 229920006362 Teflon® Polymers 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 108010004469 allophycocyanin Proteins 0.000 claims 1
- 229950008560 almecillin Drugs 0.000 claims 1
- 230000003698 anagen phase Effects 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000006286 aqueous extract Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000012911 assay medium Substances 0.000 claims 1
- 239000012148 binding buffer Substances 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims 1
- 229960002495 buspirone Drugs 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 239000013553 cell monolayer Substances 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims 1
- 239000007931 coated granule Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 230000021615 conjugation Effects 0.000 claims 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 claims 1
- 238000007405 data analysis Methods 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 238000013461 design Methods 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims 1
- 229950006878 dextrorphan Drugs 0.000 claims 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 230000008034 disappearance Effects 0.000 claims 1
- 231100000673 dose–response relationship Toxicity 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 238000011067 equilibration Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- 229940097043 glucuronic acid Drugs 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 claims 1
- 229940097277 hygromycin b Drugs 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000003674 kinase activity assay Methods 0.000 claims 1
- 238000002350 laparotomy Methods 0.000 claims 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 claims 1
- 239000006166 lysate Substances 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 229960000906 mephenytoin Drugs 0.000 claims 1
- 238000006241 metabolic reaction Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000001589 microsome Anatomy 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 229960005127 montelukast Drugs 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 229920001778 nylon Polymers 0.000 claims 1
- 230000004783 oxidative metabolism Effects 0.000 claims 1
- 229960005489 paracetamol Drugs 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 claims 1
- 239000008191 permeabilizing agent Substances 0.000 claims 1
- 229960003893 phenacetin Drugs 0.000 claims 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229910000027 potassium carbonate Inorganic materials 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229960001404 quinidine Drugs 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 238000002165 resonance energy transfer Methods 0.000 claims 1
- 230000002441 reversible effect Effects 0.000 claims 1
- 238000012552 review Methods 0.000 claims 1
- 239000012047 saturated solution Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
- 229960005001 ticlopidine Drugs 0.000 claims 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 claims 1
- 229960003741 tranylcypromine Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 239000011534 wash buffer Substances 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 abstract description 3
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 abstract 1
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 125000000217 alkyl group Chemical group 0.000 description 12
- 125000003118 aryl group Chemical group 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- 208000024172 Cardiovascular disease Diseases 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229910052602 gypsum Inorganic materials 0.000 description 2
- 239000010440 gypsum Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000037999 tubulointerstitial fibrosis Diseases 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 240000002329 Inga feuillei Species 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- WFIHKLWVLPBMIQ-UHFFFAOYSA-N [1,3]thiazolo[5,4-b]pyridine Chemical class C1=CN=C2SC=NC2=C1 WFIHKLWVLPBMIQ-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- OHIHEJTUXNQOPM-UHFFFAOYSA-N methyl 6-aminopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(N)=N1 OHIHEJTUXNQOPM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 231100000857 poor renal function Toxicity 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591710P | 2012-01-27 | 2012-01-27 | |
| PCT/US2013/022997 WO2013112741A1 (en) | 2012-01-27 | 2013-01-24 | Apoptosis signal-regulating kinase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491283A1 EA201491283A1 (ru) | 2014-12-30 |
| EA024746B1 true EA024746B1 (ru) | 2016-10-31 |
Family
ID=47684038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491283A EA024746B1 (ru) | 2012-01-27 | 2013-01-24 | Ингибитор регулирующей апоптотические сигналы киназы |
Country Status (39)
Families Citing this family (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| US20150148345A1 (en) | 2013-11-26 | 2015-05-28 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| JP2017503001A (ja) | 2014-01-20 | 2017-01-26 | ギリアード サイエンシーズ， インコーポレイテッド | がんを処置するための療法 |
| US20150342943A1 (en) * | 2014-06-03 | 2015-12-03 | Gilead Sciences, Inc. | Methods of treating liver disease |
| TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
| MX2017003933A (es) * | 2014-09-24 | 2017-06-30 | Gilead Sciences Inc | Metodos de tratamiento de la enfermedad hepatica. |
| PT3237404T (pt) | 2014-12-23 | 2021-01-19 | Gilead Sciences Inc | Processos de preparação de inibidores ask1 |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CN109879859B (zh) | 2015-07-06 | 2022-01-25 | 吉利德科学公司 | Cot调节剂及其使用方法 |
| US20190054090A1 (en) | 2015-10-01 | 2019-02-21 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
| JP2018534263A (ja) * | 2015-10-02 | 2018-11-22 | ギリアード サイエンシーズ， インコーポレイテッド | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
| AU2016370916A1 (en) | 2015-12-17 | 2018-06-07 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
| CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
| JP2019513737A (ja) | 2016-04-08 | 2019-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | がん、炎症性疾患および自己免疫疾患を処置するための組成物および方法 |
| MX2018015584A (es) | 2016-06-13 | 2019-09-18 | I Mab | Anticuerpos anti-pd-l1 y usos de los mismos. |
| WO2018026835A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US20180133212A1 (en) | 2016-11-03 | 2018-05-17 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
| JP2019533706A (ja) | 2016-11-11 | 2019-11-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置する方法 |
| US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
| AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| BR112019014756B1 (pt) | 2017-01-22 | 2021-08-10 | Fujian Cosunter Pharmaceutical Co., Ltd | Composto inibidor de ask1 e composição farmacêutica que o compreende |
| AU2018209573B2 (en) * | 2017-01-22 | 2020-08-13 | Fujian Akeylink Biotechnology Co., Ltd. | ASK1 inhibitor and preparation method and use thereof |
| PT3383916T (pt) | 2017-01-24 | 2022-03-30 | I Mab Biopharma Us Ltd | Anticorpos anti-cd73 e seus usos |
| JP7014811B2 (ja) | 2017-02-24 | 2022-02-01 | ギリアド サイエンシズ， インコーポレイテッド | ブルトン型チロシンキナーゼの阻害剤 |
| EP3585789A1 (en) | 2017-02-24 | 2020-01-01 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2018157277A1 (en) | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
| CN115504986B (zh) * | 2017-03-03 | 2024-05-14 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶抑制剂及其制备方法和应用 |
| JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
| TW201900167A (zh) | 2017-03-28 | 2019-01-01 | 美商基利科學股份有限公司 | 治療肝疾病之方法 |
| CA3059883A1 (en) | 2017-04-12 | 2018-10-18 | Gilead Sciences, Inc. | Methods of treating liver disease |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218044A2 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals Inc | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218042A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018218051A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| WO2018231851A1 (en) | 2017-06-13 | 2018-12-20 | Gilead Sciences, Inc. | Methods of treating liver fibrosis |
| TW201908306A (zh) * | 2017-07-18 | 2019-03-01 | 大陸商南京聖和藥業股份有限公司 | 作為ask抑制劑的雜環化合物及其應用 |
| US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109456308B (zh) * | 2017-09-06 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
| WO2019047094A1 (en) * | 2017-09-07 | 2019-03-14 | Eli Lilly And Company | CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS |
| US10370352B2 (en) | 2017-09-07 | 2019-08-06 | Eli Lilly And Company | Cyclobutyl-imidazolidinone compounds |
| WO2019047161A1 (en) | 2017-09-08 | 2019-03-14 | Eli Lilly And Company | IMIDAZOLIDINE COMPOUNDS |
| US11034671B2 (en) | 2017-09-08 | 2021-06-15 | Sichuan Haisco Pharmaceutical Co., Ltd. | Apoptosis signal-regulating kinase inhibitors and uses thereof |
| CN109232538B (zh) * | 2017-10-12 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
| CN107793400B (zh) * | 2017-10-31 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用 |
| WO2019094777A1 (en) | 2017-11-13 | 2019-05-16 | Gilead Sciences, Inc. | Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| CN111801314B (zh) | 2018-01-02 | 2023-10-31 | 西尔洛克治疗公司 | Ask1抑制剂化合物及其用途 |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| WO2019200267A1 (en) | 2018-04-12 | 2019-10-17 | Terns, Inc. | Tricyclic ask1 inhibitors |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
| WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| MX2020011225A (es) | 2018-05-02 | 2021-01-20 | Enanta Pharm Inc | Tetrazol que contiene inhibidores de la cinasa 1 reguladora de la señal de apoptosis y métodos de uso de los mismos. |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| JP2021523151A (ja) | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
| KR102732008B1 (ko) | 2018-05-14 | 2024-11-20 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| WO2020006429A1 (en) * | 2018-06-28 | 2020-01-02 | Hepatikos Therapeutics, Llc | Ask1 isoindolin-1-one inhibitors and methods of use thereof |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| JP7096460B2 (ja) * | 2018-07-20 | 2022-07-06 | 福建▲広▼生中霖生物科技有限公司 | Ａｓｋ１阻害剤としての結晶形、その製造方法及び利用 |
| WO2020041417A1 (en) | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| KR102298546B1 (ko) | 2018-10-18 | 2021-09-08 | 에이치케이이노엔 주식회사 | 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| CN111170995A (zh) * | 2018-11-09 | 2020-05-19 | 山东轩竹医药科技有限公司 | Ask1抑制剂及其应用 |
| US11345699B2 (en) | 2018-11-19 | 2022-05-31 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| CN109608441A (zh) * | 2018-12-26 | 2019-04-12 | 都创(上海)医药科技有限公司 | 一种ask1抑制剂的合成工艺 |
| US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| CN109813915A (zh) * | 2019-02-15 | 2019-05-28 | 浠思（上海）生物技术有限公司 | 利用htrf一步法筛选激酶抑制剂的方法 |
| EP3927683A1 (en) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| KR20240135055A (ko) | 2019-03-11 | 2024-09-10 | 길리애드 사이언시즈, 인코포레이티드 | 화합물의 제제 및 그의 용도 |
| WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| TWI855100B (zh) * | 2019-06-26 | 2024-09-11 | 印度商人類製藥有限公司 | 新型細胞凋亡訊號調節激酶1抑制劑 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| US11795223B2 (en) | 2019-10-18 | 2023-10-24 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
| US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
| EP4126231A1 (en) | 2020-03-30 | 2023-02-08 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| CN115397824B (zh) | 2020-04-02 | 2024-10-22 | 吉利德科学公司 | 用于制备cot抑制剂化合物的方法 |
| US20240043427A1 (en) | 2020-05-01 | 2024-02-08 | Gilead Sciences, Inc. | Cd73 compounds |
| US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| CN113831323B (zh) * | 2020-06-24 | 2025-08-29 | 武汉人福创新药物研发中心有限公司 | 芳杂环酰胺类化合物及其用途 |
| CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
| CN114470217B (zh) * | 2020-11-24 | 2023-06-20 | 深圳微芯生物科技股份有限公司 | 预防和治疗代谢异常或炎症引起的组织损伤的药物组合物 |
| US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| WO2022212194A1 (en) | 2021-03-29 | 2022-10-06 | Gilead Sciences, Inc. | Khk inhibitors |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CN114246866B (zh) * | 2021-04-28 | 2023-09-12 | 深圳微芯生物科技股份有限公司 | 用于治疗慢性肾病的药物及其用途 |
| CN117295717A (zh) | 2021-05-11 | 2023-12-26 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| JP7691522B2 (ja) | 2021-05-13 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022375782A1 (en) | 2021-10-28 | 2024-05-02 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2025509662A (ja) | 2022-03-24 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CA3260083A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences Inc | CD73 COMPOUNDS |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| US20240254118A1 (en) | 2022-12-22 | 2024-08-01 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN115844887B (zh) * | 2022-12-28 | 2023-09-08 | 中国人民解放军空军军医大学 | Selonsertib在制备治疗癌症的药物中的用途 |
| AU2024252725A1 (en) | 2023-04-11 | 2025-11-06 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121079300A (zh) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024236595A1 (en) * | 2023-05-18 | 2024-11-21 | Council Of Scientific And Industrial Research | Protacs for ask1 protein degradation: preparation and use thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025054347A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011008709A1 (en) * | 2009-07-13 | 2011-01-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| WO2012003387A1 (en) * | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034946A1 (en) | 1997-02-12 | 1998-08-13 | Massachusetts Institute Of Technology | Daxx, a novel fas-binding protein that activates jnk and apoptosis |
| SI1144600T1 (sl) | 1999-03-19 | 2008-12-31 | Aventis Pharma Inc | AKT-3-nukleinske kisline, polipeptidi in njihove uporabe |
| US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
| AU2001275330A1 (en) * | 2000-06-07 | 2001-12-17 | Marc D. Andelman | Fluid and electrical connected flow-through electrochemical cells, system and method |
| US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
| EP1661581A1 (en) | 2003-07-28 | 2006-05-31 | Osaka Industrial Promotion Organization | Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
| CA2581375A1 (en) | 2004-09-27 | 2006-04-06 | Kosan Biosciences Incorporated | Specific kinase inhibitors |
| EP1819341A4 (en) | 2004-11-10 | 2011-06-29 | Synta Pharmaceuticals Corp | IL-12 MODULATORY CONNECTIONS |
| EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
| US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
| JPWO2008016131A1 (ja) | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| WO2008042867A2 (en) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
| AU2007333106A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
| EP1942104A1 (en) | 2006-12-20 | 2008-07-09 | sanofi-aventis | Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals |
| US8104727B2 (en) | 2007-03-12 | 2012-01-31 | Denis Joanisse | Adjustable article support |
| WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
| AU2008291075A1 (en) | 2007-08-31 | 2009-03-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
| US8461163B2 (en) | 2008-03-31 | 2013-06-11 | Takeda Pharmaceutical Company Limited | Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1 |
| US8178555B2 (en) | 2008-06-24 | 2012-05-15 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
| US20110263441A1 (en) | 2008-10-15 | 2011-10-27 | Golub Todd R | Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders |
| US20110294693A1 (en) | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
| US20120010272A1 (en) | 2009-03-27 | 2012-01-12 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
| PT2531501E (pt) | 2010-02-03 | 2014-02-17 | Takeda Pharmaceutical | Inibidores da cinase de regulação do sinal de apoptose 1 |
| EP2534145A4 (en) | 2010-02-08 | 2013-09-11 | Kinagen Inc | THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE |
| EP2550266B1 (en) | 2010-03-24 | 2018-05-09 | Amitech Therapeutics Solutions, Inc. | Heterocyclic compounds useful for kinase inhibition |
| WO2012068464A2 (en) | 2010-11-18 | 2012-05-24 | University Of Delaware | Methods of treating and preventing thrombotic diseases using ask1 inhibitors |
| US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
| CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
| EP2718721A4 (en) | 2011-06-07 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | CIRCULATING BIOMARKERS FOR CANCER |
| TW201837023A (zh) | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| US8924765B2 (en) | 2011-07-03 | 2014-12-30 | Ambiq Micro, Inc. | Method and apparatus for low jitter distributed clock calibration |
| UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| PT3237404T (pt) | 2014-12-23 | 2021-01-19 | Gilead Sciences Inc | Processos de preparação de inibidores ask1 |
-
2013
- 2013-01-11 UY UY0001034573A patent/UY34573A/es not_active Application Discontinuation
- 2013-01-24 JP JP2014554828A patent/JP5770950B2/ja active Active
- 2013-01-24 SG SG11201404348UA patent/SG11201404348UA/en unknown
- 2013-01-24 CA CA3026700A patent/CA3026700C/en active Active
- 2013-01-24 HU HUE13703675A patent/HUE028641T2/en unknown
- 2013-01-24 KR KR1020177032774A patent/KR20170128622A/ko not_active Ceased
- 2013-01-24 CN CN201380006957.0A patent/CN104080771B/zh active Active
- 2013-01-24 EP EP13703675.2A patent/EP2807151B1/en active Active
- 2013-01-24 MD MDA20140082A patent/MD4601B1/ro not_active IP Right Cessation
- 2013-01-24 PT PT137036752T patent/PT2807151E/pt unknown
- 2013-01-24 ES ES13703675.2T patent/ES2558203T3/es active Active
- 2013-01-24 EA EA201491283A patent/EA024746B1/ru unknown
- 2013-01-24 HR HRP20151399TT patent/HRP20151399T1/hr unknown
- 2013-01-24 ME MEP-2016-5A patent/ME02322B/me unknown
- 2013-01-24 MX MX2014009075A patent/MX2014009075A/es active IP Right Grant
- 2013-01-24 KR KR1020187037026A patent/KR20190000898A/ko not_active Ceased
- 2013-01-24 RS RS20160019A patent/RS54492B1/sr unknown
- 2013-01-24 CA CA2862030A patent/CA2862030C/en active Active
- 2013-01-24 KR KR1020157036387A patent/KR101707764B1/ko active Active
- 2013-01-24 AP AP2014007836A patent/AP2014007836A0/xx unknown
- 2013-01-24 CA CA3026738A patent/CA3026738C/en active Active
- 2013-01-24 SI SI201330109A patent/SI2807151T1/sl unknown
- 2013-01-24 WO PCT/US2013/022997 patent/WO2013112741A1/en not_active Ceased
- 2013-01-24 MX MX2015009422A patent/MX365954B/es unknown
- 2013-01-24 UA UAA201407926A patent/UA112098C2/uk unknown
- 2013-01-24 NZ NZ739339A patent/NZ739339A/en unknown
- 2013-01-24 AU AU2013201586A patent/AU2013201586C1/en active Active
- 2013-01-24 CN CN201811215092.XA patent/CN109438418B/zh active Active
- 2013-01-24 KR KR1020147023533A patent/KR101582065B1/ko active Active
- 2013-01-24 PL PL13703675T patent/PL2807151T3/pl unknown
- 2013-01-24 DK DK13703675.2T patent/DK2807151T3/en active
- 2013-01-24 BR BR112014018355-4A patent/BR112014018355B1/pt active IP Right Grant
- 2013-01-24 US US13/748,901 patent/US8742126B2/en active Active
- 2013-01-24 PE PE2014001153A patent/PE20141822A1/es active IP Right Grant
- 2013-01-24 KR KR1020177003620A patent/KR101799739B1/ko active Active
- 2013-01-25 TW TW105128669A patent/TWI634890B/zh active
- 2013-01-25 TW TW103125752A patent/TWI561514B/zh active
- 2013-01-25 AR ARP130100241A patent/AR089818A1/es active IP Right Grant
- 2013-01-25 TW TW102102991A patent/TWI487523B/zh active
- 2013-01-25 TW TW107127139A patent/TW201916877A/zh unknown
-
2014
- 2014-04-16 US US14/254,342 patent/US9254284B2/en active Active
- 2014-04-16 US US14/254,359 patent/US9333197B2/en active Active
- 2014-07-10 IL IL233598A patent/IL233598A/en active IP Right Grant
- 2014-07-11 MA MA37202A patent/MA35861B1/fr unknown
- 2014-07-17 ZA ZA2014/05260A patent/ZA201405260B/en unknown
- 2014-07-22 IN IN6174DEN2014 patent/IN2014DN06174A/en unknown
- 2014-07-25 PH PH12014501697A patent/PH12014501697B1/en unknown
- 2014-07-25 CL CL2014001988A patent/CL2014001988A1/es unknown
- 2014-07-25 MX MX2019007348A patent/MX2019007348A/es unknown
- 2014-08-26 CO CO14186994A patent/CO7061073A2/es unknown
- 2014-08-29 CR CR20140405A patent/CR20140405A/es unknown
-
2015
- 2015-06-10 IL IL239311A patent/IL239311B/en active IP Right Grant
-
2016
- 2016-02-15 SM SM201600047T patent/SMT201600047B/it unknown
- 2016-02-16 CY CY20161100129T patent/CY1117201T1/el unknown
- 2016-04-27 US US15/140,204 patent/US9750730B2/en active Active
-
2017
- 2017-04-19 US US15/491,689 patent/US9873682B2/en active Active
- 2017-12-13 US US15/840,429 patent/US20180099950A1/en not_active Abandoned
-
2018
- 2018-03-07 IL IL257965A patent/IL257965A/en unknown
-
2019
- 2019-01-11 US US16/246,199 patent/US10508100B2/en active Active
- 2019-11-19 AR ARP190103385A patent/AR117113A2/es not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011008709A1 (en) * | 2009-07-13 | 2011-01-20 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
| WO2012003387A1 (en) * | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA024746B1 (ru) | Ингибитор регулирующей апоптотические сигналы киназы | |
| AU2015201188B2 (en) | Apoptosis signal-regulating kinase inhibitor | |
| HK40001058A (en) | Apoptosis signal-regulating kinase inhibitor | |
| HK40001058B (zh) | 细胞凋亡信号调节激酶抑制剂 | |
| HK1204324B (en) | Apoptosis signal-regulating kinase inhibitor |